Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Field evaluation of a broadly sensitive HIV-1 In-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country
Journal of Clinical Microbiology, Volume 51, No. 2, Year 2013
Notification
URL copied to clipboard!
Description
HIV-1 drug resistance (HIVDR) assays are important tools in clinical management of HIV-infected patients on antiretroviral therapy (ART) and surveillance of drug-resistant variants at population levels. The high cost associated with commercial assays hinders their use in resource-limited settings. We adopted and validated a low-cost in-house assay using 68 matched plasma and dried blood spot (DBS) samples with a median viral load (VL) of 58,187 copies/ml, ranging from 253 to 3,264,850 against the commercial assay ViroSeq. Results indicated that the in-house assay not only had a higher plasma genotyping rate than did ViroSeq (94% versus 78%) but also was able to genotype 89.5% (51/57) of the matched DBS samples with VLs of>1,000 copies/ml. The sensitivity in detecting DR mutations by the in-house assay was 98.29% (95% confidence interval [CI], 97.86 to 98.72) on plasma and 96.54 (95% CI, 95.93 to 97.15) on DBS, and the specificity was 99.97% (95% CI, 99.91 to 100.00) for both sample types compared to ViroSeq. The minor DR mutation differences detected by the in-house assay against ViroSeq did not result in clinical significance. In addition, cost analysis showed that the in-house assay could reduce the genotyping cost by about 60% for both plasma and DBS compared to ViroSeq. This field condition evaluation highlights the potential utility of a cost-effective, subtype-independent, in-house genotyping assay using both plasma and DBS specimens for HIVDR clinical monitoring and population-based surveillance in resource-limited settings. Copyright © 2013, American Society for Microbiology.
Authors & Co-Authors
Inzaule, Seth Chekata
Kenya, Nairobi
Centre for Global Health Research
Yang, Chunfu
United States, Atlanta
National Center for Hiv, Viral Hepatitis, Std, and tb Prevention
Kasembeli, Alex N.
Kenya, Nairobi
Centre for Global Health Research
Nafisa, Lillian G.
Kenya, Nairobi
Centre for Global Health Research
Okonji, Jully
Kenya, Nairobi
Centre for Global Health Research
Oyaro, Boaz
Kenya, Nairobi
Centre for Global Health Research
Lando, Richard
Kenya, Nairobi
Centre for Global Health Research
Mills, Lisa A.
United States, Atlanta
Centers for Disease Control and Prevention
Laserson, Kayla F.
United States, Atlanta
Centers for Disease Control and Prevention
Thomas, Timothy K.
United States, Atlanta
Centers for Disease Control and Prevention
N’kengasong, John Nkemngong
United States, Atlanta
National Center for Hiv, Viral Hepatitis, Std, and tb Prevention
Zeh, Clement E.
United States, Atlanta
Centers for Disease Control and Prevention
Statistics
Citations: 25
Authors: 12
Affiliations: 3
Identifiers
Doi:
10.1128/JCM.02347-12
ISSN:
00951137
e-ISSN:
1098660X
Research Areas
Cancer
Genetics And Genomics
Infectious Diseases
Study Design
Cross Sectional Study